Onset of action following formoterol turbuhaler® and salbutamol pMDI in reversible chronic airway obstruction

Pulmonary Pharmacology and Therapeutics

Volumn 15, Issue 2, 2002, Pages 97-102

  Cazzola, M ^a   Grella, E ^b   Matera, M G ^c   Mazzarella, G ^b   Marsico, S A ^b  

^a CARDARELLI HOSPITAL   (Italy)

^b Department of Cardiothoracic and Respiratory Sciences   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Asthma; COPD; Formoterol; Onset of action; Salbutamol

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; FORMOTEROL; SALBUTAMOL;

ADULT; AGED; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INHALER; MALE; METERED DOSE INHALER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

EID: 0036311635     PISSN: 10945539     EISSN: None     Source Type: Journal    
DOI: 10.1006/pupt.2001.0336     Document Type: Review

References (18)

1. Oxis® (formoterol given by Turbuhaler®) showed as rapid an onset of action as salbutamol given by a pMDI
2. Onset of action of single doses of formoterol administered via Turbuhaler in patients with stable COPD
3. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: Onset of action, duration of effect and potency
4. Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease
5. Effects of formoterol in apparently poorly reversible chronic obstructive pulmonary disease
6. Tolerability to high doses of formoterol and terbutaline via Turbuhaler® for 3 days in stable asthmatic patients
7. Standardization of spirometry - 1987 update
8. Use of formoterol (Oxis® Turbuhaler®) as needed in moderate to severe asthma reduces the number of inhalers whilst maintaining effectiveness
9. Formoterol on airway smooth muscle and human lung mast cells: A comparison with salbutamol and salmeterol
10. Relaxant effects and durations of action of formoterol and salmeterol on the isolated human bronchus
11. Formoterol, fenoterol, and salbutamol as partial agonists for relaxation of maximally contracted guinea pig tracheae: Comparison of relaxation with receptor binding
12. Time course of bronchodilating effect of inhaled formoterol, a potent and long acting sympathomimetic
13. Time course and duration of bronchodilatation with formoterol dry powder in patients with stable asthma
14. The pharmacologic and clinical properties of Oxis (formoterol) Turbuhaler
15. The inhalation device influences lung deposition and bronchodilating effect of terbutaline
16. Concepts of establishing clinical bioequivalence of chlorofluorocarbon and hydrofluoroalkane beta-agonists